1000787-75-6

Usage

references

[1]. zeuzem s, andreone p, pol s, lawitz e, diago m, roberts s, focaccia r, younossi z, foster gr, horban a et al: telaprevir for retreatment of hcv infection. n engl j med 2011, 364(25):2417-2428.[2]. wong ka, xu s, martin r, miller md, mo h: tegobuvir (gs-9190) potency against hcv chimeric replicons derived from consensus ns5b sequences from genotypes 2b, 3a, 4a, 5a, and 6a. virology 2012, 429(1):57-62.[3]. shih ih, vliegen i, peng b, yang h, hebner c, paeshuyse j, purstinger g, fenaux m, tian y, mabery e et al: mechanistic characterization of gs-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis c virus ns5b polymerase. antimicrob agents chemother 2011, 55(9):4196-4203.[4]. behrens se, tomei l, de francesco r: identification and properties of the rna-dependent rna polymerase of hepatitis c virus. embo j 1996, 15(1):12-22.[5]. hebner cm, han b, brendza km, nash m, sulfab m, tian y, hung m, fung w, vivian rw, trenkle j et al: the hcv non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit ns5b polymerase function. plos one 2012, 7(6):e39163.

Upstream product

• 1099778-81-0 3-(2,4-bis-trifluoromethyl-phenyl)-6-chloromethyl-pyridazine 
• 89075-43-4 2-(2-fluorophenyl)-3H-imidazo[4,5-c]pyridine 
• 153254-09-2 2,4-bis(trifluoromethyl)phenylboronic acid 
• 1000787-76-7 5-[6-chloro-pyridazin-3-ylmethyl]-2-(2-fluoro-phenyl)-5H-imidazo[4,5-c]pyridine 
• 1121-79-5 3-chloro-6-methylpyridazine 
• 120276-59-7 3-chloro-6-pyridazinyl methyl chloride 

Relevant academic research and scientific papers

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

PHARMACEUTICAL COMBINATIONS USEFUL FOR TREATING HCV

This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.

PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV

This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.

PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV

This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.

Crystalline pyridazine compound

A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.

Novel pyridazine compound and use thereof

A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.